All In Biotech

Drug Trial Radar · NCT07707674

Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects With Metastatic Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Evopoint Biosciences Inc.Industry
Sponsor type
Industry
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer

Conditions

  • Metastatic Pancreatic Cancer

Interventions

  • XNW28012Drug

    XNW28012 is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targeting Tissue Factor (TF) and a topoisomerase I inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: From the first dose of study treatment through 30 days after the last dose of study treatment.
  2. Incidence of Serious Adverse Events (SAEs)Time frame: From the first dose of study treatment through 30 days after the last dose of study treatment.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Karmanos Cancer Institute

    Detroit, Michigan

  • START - Midwest

    Grand Rapids, Michigan

  • START - New York Long Island

    Lake Success, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Oklahoma University Health Sciences Center

    Oklahoma City, Oklahoma

  • SCRI Oncology Partners

    Nashville, Tennessee

  • SCRI at Mary Crowley

    Dallas, Texas

  • START - San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.